EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
11.13 USD
-0.27%
Market Closed
Updated:
May 29, 2024
EyePoint Pharmaceuticals Inc
Other Long-Term Assets
|
EyePoint Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Other Long-Term Assets
$150k
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$5.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$16.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$11.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$10.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is EyePoint Pharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
150k
USD
150k
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Other Long-Term Assets amounts to 150k USD.
What is EyePoint Pharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-7%
-7%
Over the last year, the Other Long-Term Assets growth was -25%. The average annual Other Long-Term Assets growth rates for EyePoint Pharmaceuticals Inc have been -9% over the past three years , -6% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
